ArticleMaterials today. Bio2026
Dual-responsive PDA-HP hydrogel enables mitochondria-targeted mild photothermal therapy for spinal cord repair.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating neurological disorder with substantial economic and psychological burdens, underscoring the urgent need for effective therapeutic strategies. Here, we developed a dual-responsive hydrogel composed of polydopamine (PDA) and heparin-poloxamer (HP) that enables controllable mild photothermal stimulation under near-infrared (NIR) irradiation. The PDA-HP hydrogel exhibited excellent biocompatibility, biodegradability, and stable photothermal conversion. In a mouse SCI model, in situ administration of PDA-HP combined with NIR irradiation markedly improved locomotor recovery and mitigated tissue damage. Mechanistically, PDA-HP/NIR therapy reduced oxidative stress, preserved mitochondrial structure, restored ATP production, and-most notably-normalized the maladaptive overexpression of heat-shock protein 70 (HSP70) induced by SCI, thereby decreasing apoptosis and promoting neuronal survival. Quantitative proteomics further identified stress-chaperone and mitochondrial pathways as major targets of this intervention. To our knowledge, this is the first study demonstrating that PDA-HP-mediated mild photothermal modulation restores mitochondrial function through HSP70 normalization in SCI. These findings highlight a mitochondria-targeted mild photothermal strategy as a promising and clinically translatable approach for spinal cord repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.